|Bid||94.64 x 800|
|Ask||101.28 x 1100|
|Day's Range||93.69 - 95.38|
|52 Week Range||90.54 - 116.49|
|Beta (3Y Monthly)||1.16|
|PE Ratio (TTM)||15.28|
|Earnings Date||Jan 30, 2019 - Feb 4, 2019|
|Forward Dividend & Yield||2.00 (2.09%)|
|1y Target Est||110.00|
Building up an investment case requires looking at a stock holistically. Today I’ve chosen to put the spotlight on Quest Diagnostics Incorporated (NYSE:DGX) due to its excellent fundamentals in more Read More...
Today I will examine Quest Diagnostics Incorporated’s (NYSE:DGX) latest earnings update (30 September 2018) and compare these figures against its performance over the past couple of years, in addition to Read More...
A grouping of such companies by Citi surfaced the likes of Walmart, McDonald's, Pfizer, Procter & Gamble, Amgen and Quest Diagnostics. While not predictive in itself, this pattern is one seen in the run-up to a bear market. Shares of quality companies have been outperforming the broad benchmarks — both before the October market correction and on the bounce of the past two weeks.
New Findings Demonstrate the Benefit of Using Genetic Markers to Aid Detection of Atrial Fibrillation Research is a Product of Quest's First National Cardiovascular Center of Excellence Based at Cleveland ...
SECAUCUS, N.J., Nov. 8, 2018 /PRNewswire/ -- Quest Diagnostics Incorporated (DGX), the world's leading provider of diagnostic information services, announced that MyQuest, used by more than six million people to see, store and share their results and health information using a smartphone, tablet or desktop computer, now supports Health Records on iPhone. In addition, Quest recently launched a MyQuest update that provides new features such as direct access testing, the ability to add dependents or other approved users, real-time scheduling and more for patients as they become more engaged in managing their healthcare decisions. "Consumers play a more active role in managing their health and wellness than ever before, and they expect the most accurate and up-to-date diagnostic information, so that they can make educated decisions," said Cathy Doherty, Senior Vice President and Group Executive, Clinical Franchise Solutions & Marketing.
NEWARK, N.J. and SECAUCUS, N.J., Nov. 8, 2018 /PRNewswire/ -- Horizon Blue Cross Blue Shield of New Jersey (Horizon BCBSNJ) announced today that it is expanding its laboratory network by adding Quest Diagnostics (DGX) as an in-network provider of diagnostic information services for 2.8 million members of Horizon BCBSNJ.
SECAUCUS, N.J., Nov. 7, 2018 /PRNewswire/ -- Quest Diagnostics Incorporated (DGX), the world's leading provider of diagnostic information services, announced the launch of QuestDirect, an enhanced consumer-initiated testing service that empowers patients to manage and take control of their healthcare by ordering health and wellness lab testing from the convenience of their home. Available in 48 states, consumers can get the diagnostic information they need to stay healthy in three simple stepsi.
SECAUCUS, N.J. and OXFORD, England and MARLBOROUGH, Mass., Nov. 6, 2018 /PRNewswire/ -- Quest Diagnostics (DGX) and Oxford Immunotec Global PLC (OXFD) today announced that Quest Diagnostics has completed its previously announced acquisition of the U.S. laboratory services business of Oxford Immunotec. The T-SPOT.TB tuberculosis and the Accutix tick-borne disease testing services are now part of Quest Diagnostics' portfolio of innovative infectious disease testing services. As part of the transaction, Oxford Immunotec will sell T-SPOT.TB test kits and related accessories to Quest Diagnostics under the terms of a long-term supply agreement.
TEMPE, Ariz., Nov. 1, 2018 /PRNewswire/ -- Sonora Quest Laboratories, Arizona's leading provider of diagnostic testing and information services, has announced a partnership with uMETHOD Health, a health technology company offering the first platform for Alzheimer's disease based on advanced artificial intelligence technology. Through the partnership, healthcare providers will have access to the RestoreU METHOD via Sonora Quest for their patients experiencing memory loss.
Relationship ensures broad access to innovative FIT test in the U.S. BRIDGEWATER, N.J., and SECAUCUS, N.J., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Clinical Genomics, a leading innovator of tests for colorectal cancer, and Quest Diagnostics (DGX), the world's leading provider of diagnostic information services, today announced a 5-year extension to their U.S. supply agreement for the InSure® ONE™ fecal immunochemical test (FIT). This agreement builds upon a long standing collaboration to provide InSure FIT and the new InSure ONE FIT for colorectal cancer screening programs.
NEW YORK, Oct. 29, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Quest to Acquire the Outreach Laboratory Service Operations of Marin General Hospital SECAUCUS, N.J. and GREENBRAE, Calif. , Oct. 25, 2018 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading ...
SECAUCUS, N.J. , Oct. 23, 2018 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, will host an Investor Day for institutional investors and ...
The size of Quest Diagnostics Incorporated (NYSE:DGX), a US$14.0b large-cap, often attracts investors seeking a reliable investment in the stock market. Big corporations are much sought after by risk-averse investors Read More...
On a per-share basis, the Secaucus, New Jersey-based company said it had net income of $1.53. Earnings, adjusted for one-time gains and costs, were $1.68 per share. The results met Wall Street expectations. ...